icon- folder.gif   Conference Reports for NATAP  
  AIDS 2010
18th International AIDS Conference (IAC)
July 18-23 2010
Vienna, Austria
Back grey_arrow_rt.gif
TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection - Inflammation
  Reported by Jules Levin
David E. Martin, PharmD*
Tobira Therapeutics, Inc.
*On behalf of TBR-652-2-201 Study Team
XVIII International AIDS Conference, Vienna, Austria 20 July 2010